Cargando…
The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
Overall survival (OS) is considered the standard clinical endpoint to support effectiveness claims in new drug applications globally, particularly for lethal conditions such as cancer. However, the source and reliability of OS in the setting of clinical trials have seldom been doubted and discussed....
Autores principales: | Huang, Huiyao, Tang, Yu, Yu, Yue, Yu, Anqi, Wu, Dawei, Fang, Hong, Wang, Shuhang, Sun, Chao, Wang, Xin, Fan, Qi, Fang, Yuan, Tang, Qiyu, Jiang, Ning, Du, Jingting, Miao, Huilei, Bai, Ying, Ma, Peiwen, Xing, Shujun, Cui, Dandan, Miao, Shuangman, Jiang, Yale, Zhu, Jingxiao, Zhu, Qi, Leng, Ye, Guo, Lan Wei, Liao, Shanmei, Shao, Yaguang, Song, Yinyin, Liu, Zeyuan, Hong, Minghuang, Luo, Suxia, Xu, Binghe, Lan, Gongtao, Li, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678947/ https://www.ncbi.nlm.nih.gov/pubmed/36426285 http://dx.doi.org/10.1016/j.lanwpc.2022.100624 |
Ejemplares similares
-
Targeting rare tumors: new focus for clinical research in China
por: Wang, Shuhang, et al.
Publicado: (2022) -
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022) -
Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
por: Wang, Shuhang, et al.
Publicado: (2022) -
Association between germ-line HLA and immune-related adverse events
por: Jiang, Ning, et al.
Publicado: (2022) -
Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention
por: Dawei, Wu, et al.
Publicado: (2022)